Tags: Mild Cognitive Impairment
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
January 11, 2019
New Funding Focuses on Prevention
The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.
blog
August 2, 2018
Top Five Highlights from AAIC 2018
The ADDF looks back at the 2018 Alzheimer's Association International Conference.
blog
March 6, 2017
Prevention: A Key to Conquering Alzheimer’s
Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials.
blog
February 21, 2017
Closing in on a Cure: Dr. Michela Gallagher and AGB101
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
blog
February 3, 2015
Early-Stage Dementia Treatment Headed to Phase 3 Clinical Trial
ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment.
announcements
January 28, 2015
New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
blog
July 17, 2014
Alzheimer’s Versus Normal Cognitive Aging
The widespread misconception that Alzheimer's disease is a typical part of aging has serious ramifications for people's health and research into a cure.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).